ClinicalTrials.gg
RecruitingNCT07454291Updated May 15, 2026

A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants

A Phase 1 interventional study of taladegib and nintedanib in Idiopathic Pulmonary Fibrosis, sponsored by Endeavor Biomedicines, Inc.. Recruiting at 2 sites in Australia. Open to participants aged 26 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Endeavor Biomedicines, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
26 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Idiopathic Pulmonary Fibrosis with a site in Australia — 11 open to participants now, 17 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · Australia.

Planned enrollment
52nd of 64
57 · median 165
Started
2026
with 7 others
Phase 1
10 of 64
3 open now
Primary completion
2026-10
later than 1 of 16 live
Registered
62nd of 64
by date
Lead sponsor
4 of 64
Endeavor Biomedicines, Inc.

Among the 64 studies in Idiopathic Pulmonary Fibrosis with a site in Australia, this one is the 52nd largest by planned enrollment, is one of 8 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 1 of the 16 other live ones, and was the 62nd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

11 of the 64 studies in Idiopathic Pulmonary Fibrosis with a site in Australia are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 26 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Idiopathic Pulmonary Fibrosis with a site in Australia, or all of them as a file.
02

Study summary

The purposes of this study are to:

  1. evaluate potential interactions between taladegib (ENV-101) and current standard-of-care (SOC) therapies for idiopathic pulmonary fibrosis (IPF), including nintedanib and pirfenidone, and
  2. more fully characterize the pharmacokinetics (PK) of taladegib (i.e., how the body absorbs, distributes, metabolizes and excretes taladegib).

This study will enroll 4 cohorts (groups) of participants. Each cohort will experience a different duration of treatment and sequestering (being housed) at the clinical site, followed by a 14-day follow-up period for safety evaluation. The longest duration of treatment for any cohort is 30 days.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • ENV-101
  • taladegib
  • drug-drug interaction
  • pharmacokinetics
04

Who can participate

Ages eligible
26 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are reproductively sterile.
  • (BMI) ≥ 18.5 and ≤ 32 kg/m2 and body weight ≥ 50 kg at study start.
  • Medically healthy with no medical history, physical examination, clinical laboratory profiles, vital signs, or (ECGs) prior to dosing, as deemed by the Investigator.
  • Able to swallow multiple capsules and tablets.
  • Participants are willing to remain on study treatment for the duration of the study and comply with all study days and procedures.
  • Participants willing to sign and have a full understanding of the .
  • Participants must be willing to be sequestered for the time period indicated for their respective cohort.

Exclusion criteria

Exclusion Criteria:

  • Chronic or current use of any prescription or over the counter medications; or acute use of prescription medications within 14 days or 5 half-lives, whichever is longer, or over the counter medications within 7 days or 5 half-lives, whichever is longer, prior to study start, or planned use during all study periods.
  • Participant is unwilling to refrain from fruits (including juices) that inhibit , including grapefruit, Seville orange, pomelo, or star fruit, beginning 7 days prior to study start through end of study.
  • Active infection with or C, or (HIV) during screening.
  • Current alcohol or drug abuse.
  • Smoking or other nicotine use (including but not limited to vaping, nicotine patch, nicotine gum or nicotine lozenge) within 3 months prior to screening, current smoker, or unwillingness to refrain from smoking for the duration of the study.
  • History or presence (per participant history) of:

    1. disease such as rheumatoid arthritis or systemic lupus erythematosus
    2. Thrombophlebitis or deep vein thrombosis
    3. Hematologic or coagulation disorders
    4. Liver disease or dysfunction; Gilbert's syndrome
    5. Renal dysfunction or glomerulonephritis
    6. Coronary artery disease
    7. Diverticular disease
    8. Congestive heart failure or ventricular dysfunction
    9. cardiovascular, gastrointestinal, pulmonary, endocrine, central nervous system disorders, or other major active and uncontrolled disease in the opinion of the Investigator.
  • History of of any type, other than in situ cervical cancer or surgically excised non-melanomatous skin cancers, within 5 years before study start.
  • Participation in a clinical research trial that included the receipt of an agent or any experimental procedure within 30 days or 5 half-lives, whichever is longer, prior to screening, during screening, or planned participation in any such trial while participating in this study.
  • Major surgery requiring hospitalization (according to the Investigator) performed within 3 months prior to screening, or planned during the course of the trial.
  • Participants with clinically significant cardiac abnormalities including but not limited to: has pacemaker; or is not in sinus rhythm during screening; or has a left bundle branch block or bifascicular block during screening; or any prior history of ventricular arrhythmia or torsades de pointes.
  • Participant is unwilling to adhere to the on-study diet provided by the clinical site during study participation.
  • Females who are pregnant or nursing.
  • Participants that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final dose of any study treatment.
  • Males who are unwilling to refrain from sperm donation for the duration of the study and for 95 days after their final dose of any study treatment.
  • Females who are unwilling to refrain from egg donation for the duration of the study and for 95 days after their final dose of any study treatment.
  • Participants with a history of a severe allergic reaction or anaphylactic reaction or known to any component of taladegib (all cohorts), nintedanib (Cohort 1), or pirfenidone (Cohorts 2 and 3).
  • Participants who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study investigative site or the study Sponsor.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (estimated)

Study arms

  • Experimental
    Cohort 1 (effect of nintedanib on taladegib pharmacokinetics)

    This cohort will receive multiple days of nintedanib twice a day to see its effect on a single dose of taladegib.

    Drug: taladegib · Drug: nintedanib

  • Experimental
    Cohort 2 (effect of pirfenidone on taladegib pharmacokinetics)

    This cohort will receive multiple days of pirfenidone three times a day to see its effect on a single dose of taladegib.

    Drug: taladegib · Drug: pirfenidone

  • Experimental
    Cohort 3 (effect of taladegib on pirfenidone pharmacokinetics)

    This cohort will receive multiple days of taladegib once a day to see its effect on a single dose of pirfenidone.

    Drug: taladegib · Drug: pirfenidone

  • Experimental
    Cohort 4 (measure taladegib pharmacokinetics)

    This cohort will receive a single dose of taladegib to measure its pharmacokinetic profile.

    Drug: taladegib

Interventions

  • low, medium or high dose tablet administered once, or once a day

    Also known as: ENV-101

  • 150 mg capsule administered twice a day

  • One, two or three 267 mg tablets administered three times a day

  • Three 267 mg tablets administered once

06

What researchers measure

Primary outcomes

  1. Cohort 1: Taladegib (ENV-101) maximum blood concentration (Cmax) after administration alone and after coadministration with nintedanib

    Time frame: Day 1 and Day 13

  2. Cohort 1: Time of taladegib maximum blood concentration (Tmax) after administration alone and after coadministration with nintedanib

    Time frame: Day 1 and Day 13

  3. Cohort 1: Taladegib absorption to time t (AUC[0-t]) after administration alone and after coadministration with nintedanib

    AUC\[0-t\] represents "area under the concentration-time curve" and measures the amount of drug that is present in the blood from the time of administration to a given time t

    Time frame: Day 1 and Day 13

  4. Cohort 1: Taladegib total absorption (AUC[0-infinity]) after administration alone and after coadministration with nintedanib

    Time frame: Day 1 and Day 13

  5. Cohort 1: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with nintedanib

    Time frame: Day 1 and Day 13

  6. Cohort 1: Taladegib half-life in the blood (T1/2) after administration alone and after coadministration with nintedanib

    Time frame: Day 1 and Day 13

  7. Cohort 1: Elimination rate constant (K[el]) for taladegib after administration alone and after coadministration with nintedanib

    K\[el\] represents the fraction of a drug that is removed from the body per unit of time.

    Time frame: Day 1 and Day 13

  8. Cohort 1: Apparent oral clearance (CL/F) of taladegib after administration alone and after coadministration with nintedanib

    Apparent oral clearance represents the volume of plasma cleared of drug per unit time after oral administration.

    Time frame: Day 1 and Day 13

  9. Cohort 1: Apparent volume of distribution (Vz/F) of taladegib after administration alone and after coadministration with nintedanib

    Apparent volume of distribution signifies how extensively a drug distributes throughout the body, accounting for bioavailability.

    Time frame: Day 1 and Day 13

  10. Cohort 2: Taladegib maximum blood concentration (Cmax) after administration alone and after coadministration with pirfenidone

    Time frame: Day 1 and Day 27

  11. Cohort 2: Time of taladegib maximum blood concentration (Tmax) after administration alone and after coadministration with pirfenidone

    Time frame: Day 1 and Day 27

  12. Cohort 2: Taladegib absorption to time t (AUC[0-t]) after administration alone and after coadministration with pirfenidone

    Time frame: Day 1 and Day 27

  13. Cohort 2: Taladegib total absorption (AUC[0-infinity]) after administration alone and after coadministration with pirfenidone

    Time frame: Day 1 and Day 27

  14. Cohort 2: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with pirfenidone

    Time frame: Day 1 and Day 27

  15. Cohort 2: Taladegib half-life in the blood (T1/2) after administration alone and after coadministration with pirfenidone

    Time frame: Day 1 and Day 27

  16. Cohort 2: Elimination rate constant (K[el]) for taladegib after administration alone and after coadministration with pirfenidone

    Time frame: Day 1 and Day 27

  17. Cohort 2: Apparent oral clearance (CL/F) of taladegib after administration alone and after coadministration with pirfenidone

    Time frame: Day 1 and Day 27

  18. Cohort 2: Apparent volume of distribution (Vz/F) of taladegib after administration alone and after coadministration with pirfenidone

    Time frame: Day 1 and Day 27

  19. Cohort 3: Pirfenidone maximum blood concentration (Cmax) after administration alone and after coadministration with taladegib

    Time frame: Day 1 and Day 6

  20. Cohort 3: Time of pirfenidone maximum blood concentration (Tmax) after administration alone and after coadministration with taladegib

    Time frame: Day 1 and Day 6

  21. Cohort 3: Pirfenidone absorption to time t (AUC[0-t]) after administration alone and after coadministration with taladegib

    Time frame: Day 1 and Day 6

  22. Cohort 3: Pirfenidone total absorption (AUC[0-infinity]) after administration alone and after coadministration with taladegib

    Time frame: Day 1 and Day 6

  23. Cohort 3: Pirfenidone extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with taladegib

    Time frame: Day 1 and Day 6

  24. Cohort 3: Pirfenidone half-life in the blood (T1/2) after administration alone and after coadministration with taladegib

    Time frame: Day 1 and Day 6

  25. Cohort 3: Elimination rate constant (K[el]) for pirfenidone after administration alone and after coadministration with taladegib

    Time frame: Day 1 and Day 6

  26. Cohort 3: Apparent oral clearance (CL/F) of pirfenidone after administration alone and after coadministration with taladegib

    Time frame: Day 1 and Day 6

  27. Cohort 3: Apparent volume of distribution (Vz/F) of pirfenidone after administration alone and after coadministration with taladegib

    Time frame: Day 1 and Day 6

  28. Cohort 4: Taladegib maximum blood concentration (Cmax) after administration alone

    Time frame: Day 1

  29. Cohort 4: Time of taladegib maximum blood concentration (Tmax) after administration alone

    Time frame: Day 1

  30. Cohort 4: Taladegib absorption to time t (AUC[0-t]) after administration alone

    Time frame: Day 1

  31. Cohort 4: Taladegib total absorption (AUC[0-infinity]) after administration alone

    Time frame: Day 1

  32. Cohort 4: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration alone

    Time frame: Day 1

  33. Cohort 4: Taladegib half-life in the blood (T1/2) after administration alone

    Time frame: Day 1

  34. Cohort 4: Elimination rate constant (K[el]) for taladegib after administration alone

    Time frame: Day 1

  35. Cohort 4: Apparent oral clearance (CL/F) of taladegib after administration alone

    Time frame: Day 1

  36. Cohort 4: Apparent volume of distribution (Vz/F) of taladegib after administration alone

    Time frame: Day 1

07

Study locations

2 of 2 sites recruiting
  • Research Site
    Brisbane, Queensland 4006, Australia
    Recruiting
  • Research Site
    Melbourne, Victoria 3004, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 6 months is below that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 6, 2026
StartActual
Apr 28, 2026
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07454291
Lead sponsor
Endeavor Biomedicines, Inc.
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Apr 28, 2026
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
May 15, 2026

Study contacts

Endeavor Clinical Trials
Contact
ebmclinical@endeavorbiomedicines.com
1-858-727-3199
Lisa Lancaster, M.D.
study director · Endeavor Biomedicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY2940680

Start the discussion